PhRMA names next CEO; Pierre Fabre takes third swing at Ebvallo approval

RegulatoryEbvalloNeutral

AI Analysis

Summary

PhRMA appoints a new CEO to replace Steve Ubl. Pierre Fabre pursues a third approval attempt for Ebvallo while recent acquisition activity benefits Mirum and AbbVie.

Outcome Details

Pierre Fabre pursuing third approval attempt for Ebvallo

Importance:3/10

Sentiment:

0.00

leadershipregulatoryM&APhRMA

Related Companies

$ABBV

Read the original article

Published by BioPharma Dive on September 30, 2026 2:18 PM

Read Original